Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Boston, Massachusetts 02115


Purpose:

This clinical study was to determine if the use of 6 months of total androgen suppression (hormonal therapy) when added to radiation therapy for localized-high risk prostate cancer would improve overall survival.


Study summary:

This was a randomized study comparing external beam radiation therapy with total androgen ablation for 6 months with radiation therapy alone. Drugs were given 2 months prior, 2 months during, and 2 months after radiation therapy. Eulexin and Lupron or Zoladex was used in this study.


Criteria:

Inclusion Criteria: - Biopsy proven prostate cancer - Negative bone scan - Lymph nodes by CT or MRI - Adequate blood work - Performance Status - ECOG 0-1 - Life expectancy of at least 10 years - >40 years of age Exclusion Criteria: - Prior history of malignancy - Prior hormonal therapy or chemotherapy - Prior pelvic radiation therapy - Unable to tolerate lying still 5-10 minutes/day


NCT ID:

NCT00116220


Primary Contact:

Principal Investigator
Anthony V D'Amico, M.D. Ph.D.
Dana-Farber Cancer Institute


Backup Contact:

N/A


Location Contact:

Boston, Massachusetts 02115
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.